5488 RESULTS
THERAPEUTICS Coya Therapeutics IL2 plus Abatacept Combination Other Inflammation In October 2021, an investigator-initiated, open-label study of COYA 302 began at the Houston Methodist Research Institute. The study planned to enroll 10 people with ALS, treat them ever
VIB/KU LeuvenBelgium
PAPER Liou JJ, Li J, Berardinelli J, Jin H, Santini T, Noh J, Farhat N, Wu M, Aizenstein HJ, Mettenburg JM, Yong WH, Head E, Ikonomovic MD, Ibrahim TS, Kofler JK, Alzheimer Biomarker Consortium—Down Syndrome
PAPER Gonzalez AI, Edwards LC, Thomas KR, Weigand AJ, Bordyug M, Brenner EK, Urias UA, Bangen KJ
PAPER Kubinski S, Claus L, Schüning T, Zeug A, Kalmbach N, Staege S, Gschwendtberger T, Petri S, Wegner F, Claus P, Hensel N
PAPER Jiang Y, Jin J, Piao Y, Yin Y, Tang L, Guan Q, Gao Y, Feng T, Wang Z
PAPER Li Z
PAPER Yu R, Peng C, Zhu J, Chen M, Zhang R
PAPER Seyedmoalemi MA, Saied-Moallemi Z
PAPER Habermas T, Gruler C, Jaeschke N, Rapp L, Weygandt R, Fußer F, Frisch S
PAPER Chen Q, Li X, Xiao W, Sun Y, Shen R, Kou X, Yang A
PAPER Zhang C, Xie S, Malek M
PAPER Lomi M, Geraci F, Del Seppia C, Dolciotti C, Del Carratore R, Bongioanni P
PAPER Lorenzini L, Barkhof F
PAPER Nishikawa M, Takeda A, Miyazawa N, Hara N, Ishii K, Ikeuchi T, Itoh Y
